Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment

Expert Opinion on Pharmacotherapy
Patricia Barragan, Daniel Podzamczer

Abstract

Lopinavir is a protease inhibitor with high specificity for HIV-1 protease formulated with ritonavir. Numerous clinical trials have shown that lopinavir/ritonavir (LPV/r) is highly effective as a component of highly active antiretroviral therapy (HAART) regimens for HIV-1 infection. In this article we provide an overview of the properties of LPV/r and the experience with its use in HIV-infected adults and adolescents. We reviewed the literature and selected the most important published articles on LPV/r and the latest posters/communications presented in conferences, with particular attention to the clinical efficacy and tolerability of LPV/r in HIV-1 infected patients. LPV/r is highly effective as a component of HAART regimens for HIV-1 infection. There is considerable experience with the drug in both treatment-naive and treatment-experienced patients. In general, LPV/r is well tolerated and its high genetic barrier to resistance favours long-term efficacy.

References

Aug 1, 1983·The Journal of Infectious Diseases·H W JaffeR M Selik
Dec 3, 1998·Antimicrobial Agents and Chemotherapy·H L ShamD W Norbeck
Jun 22, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E P AcostaC V Fletcher
Jan 11, 2001·Drugs·M Hurst, D Faulds
Feb 28, 2002·Expert Opinion on Pharmacotherapy·Nadeem A QaziAnton L Pozniak
Jun 28, 2002·The New England Journal of Medicine·Sharon WalmsleyUNKNOWN M98-863 Study Team
Mar 29, 2003·Drugs·Risto S Cvetkovic, Karen L Goa
Jan 27, 2004·Antimicrobial Agents and Chemotherapy·Odile LaunayOlivier Lortholary
Mar 23, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Esteban MartínezJosé M Gatell
Apr 20, 2004·AIDS·Thanh Doco-LecompteChristian Rabaud
Aug 25, 2004·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Robert ColebundersSteven Callens
Aug 31, 2004·Revista Da Sociedade Brasileira De Medicina Tropical·Jorge Francisco C PintoCarlos Alberto Morais-de-Sá
Dec 21, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Eugènia NegredoBonaventura Clotet
Apr 22, 2006·Therapeutic Drug Monitoring·Tania R C VergaraPaulo F Barroso
Jul 6, 2006·JAMA : the Journal of the American Medical Association·Bridget M Kuehn
Sep 22, 2006·AIDS·Alice M StekJennifer S Read
Feb 3, 2007·Expert Review of Anti-infective Therapy·Darrell Tan, Sharon Walmsley

❮ Previous
Next ❯

Citations

Apr 20, 2011·Expert Opinion on Drug Metabolism & Toxicology·Mona Arab-AlameddineChantal Csajka
Dec 8, 2009·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·S K Lam, T B Ng
Jun 20, 2020·Médecine sciences : M/S·Dylan JuckelSandrine Belouzard
May 10, 2017·Chemistry : a European Journal·Juliet M Alderson, Jennifer M Schomaker
Sep 29, 2020·Frontiers in Oncology·Rahaba MarimaClement Penny
Oct 13, 2020·Frontiers in Pharmacology·Chandan SarkarDaniela Calina
Apr 26, 2020·Brain, Behavior, and Immunity·Jiancheng ZhangKenji Hashimoto
Jan 23, 2021·International Journal of Molecular Sciences·Mohamed Amine JmelMichalis Kotsyfakis
Feb 24, 2021·AIDS Research and Human Retroviruses·Jovana MilicGiovanni Guaraldi
May 25, 2021·Critical Reviews in Analytical Chemistry·Carolina Trajano VelozoValéria Pereira de Sousa
Aug 31, 2021·Russian Journal of Bioorganic Chemistry· Zahraa Talib KhudhairBaram Hamah-Ameen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

© 2022 Meta ULC. All rights reserved